New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. Anti-thymocyte globulin is indicated for the prophylaxis of renal graft rejection as well as the treatment of steroid-resistant renal transplant rejection. Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. However, 15−35% of transplant recipients will experience one episode of acute rejection in the first year. Giving antibody to deplete thymocytes (T cells) is one way to suppress the immune system to prevent or reverse graft rejection.
Anti-thymocyte globulin
Anti-thymocyte globulin is a polyclonal antibody against human T cells. It is a gamma immunoglobulin produced by immunising rabbits. As well as depleting T cells in the circulation, anti-thymocyte globulin is also thought to reduce T cell proliferation, homing and cytotoxic effects within the body. Depletion of T cells occurs within a day of starting intravenous treatment.
This immunoglobulin has been compared to other treatments in renal transplant patients who are also receiving other immunosuppressant drugs. In a randomised trial of 72 patients, anti-thymocyte globulin was more effective at preventing acute rejection during the first year after transplantation than a similar polyclonal antibody derived from horses (4% vs 25% patients had acute rejection). 1 Five years after surgery, patient survival was similar for both treatments, but graft survival was significantly better in patients treated with anti-thymocyte globulin (77%) compared to those treated with the horse antibody (54%). 2 The rabbit polyclonal has also been compared to basiliximab (an antibody directed towards the interleukin-2 receptor) for the prevention of acute rejection in 278 renal transplant patients. Although there was a lower incidence of biopsy-proven acute rejection with anti-thymocyte globulin compared to basiliximab (16% vs 26% of patients), approximately half of the patients in both groups had acute rejection, delayed graft function, graft loss or had died after one year. 3 In another trial, the rabbit antibody was found to be as effective as a horse antibody at reversing acute rejection episodes (return of serum creatinine to baseline levels). After one year, there was no significant difference in overall graft survival between the two treatments (83% vs 75% of patients). Response to treatment depended on the severity of the initial rejection episode. 4 Anti-thymocyte globulin is also indicated for refractory or relapsing aplastic anaemia. This is an autoimmune disease resulting from the destruction of pluripotent stem cells in the bone marrow. Depletion of these stem cells reduces the number of red and white blood cells and platelets. Anti-thymocyte globulin is thought to benefit these patients by preventing activation and clonal expansion of cytotoxic T cells which are involved in mediating the disease.
The approval of anti-thymocyte globulin for the treatment of aplastic anaemia is based on an uncontrolled trial of 30 adults and children who had not responded to a course of immunosuppressive therapy (which included a horse antilymphocyte antibody). These patients were given a second course of treatment consisting of rabbit anti-thymocyte globulin for 1−5 days plus cyclosporin for 1−180 days and in addition most received granulocyte colony stimulating factor for 1−90 days.
After a median of 95 days, 23 of the 30 patients had responded to treatment, which was defined as transfusion not required for at least one month. (Women were less likely to respond than men.)
After two and a half years, 93% of the patients were still alive. One patient had died early during treatment from sepsis. 5 Following intravenous administration of this drug, fever, chills, dyspnoea, nausea, diarrhoea, changes in blood pressure, malaise, rash and headache consistent with cytokine release syndrome have been reported. Anaphylaxis has also occurred.
Reducing the infusion rate may help to reduce the incidence and severity of these adverse events. Premedication with paracetamol, corticosteroids and/or antihistamines is also recommended. This antibody is contraindicated in patients with hypersensitivity to rabbit proteins. Galsulfase is a recombinant form of acetylgalactosamine sulfatase, produced using Chinese hamster ovarian cells. The solution has to be infused intravenously over at least four hours.
Although the half-life of galsulfase is less than 30 minutes, it only needs to be infused once a week.
As mucopolysaccharidosis VI is a very rare disease the main trial of galsulfase only included 39 patients. They were given a weekly infusion of the enzyme or a placebo for 24 weeks.
Although the patients were randomised, there was a significant baseline difference between the groups. Before treatment the mean distance patients in the galsulfase group could walk in The assessment of galsulfase was complicated by the imbalance between the groups in the clinical trial. 1 Re-analysis of the data by regulatory authorities was needed to confirm the efficacy of the enzyme. There is also evidence, from a 24-week extension of the trial, that patients who switch to galsulfase from placebo will increase the distance they can walk in 12 minutes (mean increase 66 metres). This extension was 'open label' so there is some uncertainty about the benefit. Galsulfase had no significant effect on joint pain and stiffness, but the trial was not powered to show a difference. 1 The efficacy of panitumumab seems to be confined to a subset of patients with tumours expressing the wild-type (non-mutated) KRAS gene (Kirsten rat sarcoma-2 virus oncogene). Following further analysis of the phase III trial, the median progressionfree survival was 12.3 weeks in patients with wild-type KRAS and 7.4 weeks in those with mutant KRAS, after receiving panitumumab. There was no difference in overall survival between the groups. 2 In total, 43% of patients in the trial were found to have KRAS mutations so this is an important factor to consider when selecting patients for panitumumab therapy.
Although panitumumab benefits some patients, it causes considerably more adverse events than supportive care alone.
Skin-related toxicity is the most common adverse effect, Answers to self-test questions 1 Health professionals should be aware that panitumumab has been associated with an increased risk of venous thromboembolic events. In the phase III trial, 12 of 231 patients had a thromboembolic event. 1 Before starting treatment it is important to first ascertain that the patient's tumour is expressing epidermal growth factor receptor.
Expression of the wild-type KRAS gene may improve a patient's response to panitumumab. However, these findings are still preliminary and need to be confirmed in further studies. manufacturer provided only the product information
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